Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis

Christian G. Bien,1 Angela Vincent,2 Michael H. Barnett,3 Albert J. Becker,4 Ingmar Blümcke,5 Francesc Graus,6 Kurt A. Jellinger,7 David E. Reuss,8 Teresa Ribalta,9 Jürgen Schlegel,10 Ian Sutton,11 Hans Lassmann12 and Jan Bauer12

1 Epilepsy Centre Bethel, Krankenhaus Mara, 33617 Bielefeld, Germany
2 Department of Clinical Neurology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
3 Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Brain and Mind Research Institute, Sydney, Australia
4 Department of Neuropathology, University of Bonn Medical Centre, 53127 Bonn, Germany
5 Department of Neuropathology, Friedrich-Alexander-University Erlangen-Nuremberg, 91054 Erlangen, Germany
6 Service of Neurology, Hospital Clinic, Institut d'Investigacion Biomédica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036 Barcelona, Spain
7 Institute of Clinical Neurobiology, Medical University of Vienna, A-1090 Vienna, Austria
8 Department of Neuropathology, University Hospital Heidelberg and German Cancer Centre (DKFZ), 69120 Heidelberg, Germany
9 Department of Pathology, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic, Universitat de Barcelona, 08036 Barcelona, Spain
10 Division of Neuropathology, Institute of Pathology, Technical University, 81675 Munich, Germany
11 Department of Neurology, St Vincent’s Hospital, Victoria Street, Darlinghurst Sydney 2010, Australia
12 Department of Neuroimmunology, Centre for Brain Research, Medical University of Vienna, A-1090 Vienna, Austria

Correspondence to: Dr Jan Bauer, Centre for Brain Research, Medical University of Vienna, Spitalgasse 4, A-1090 Vienna, Austria
E-mail: jan.bauer@meduniwien.ac.at

Classical paraneoplastic encephalitis syndromes with ‘onconeural’ antibodies directed to intracellular antigens, and the recently described paraneoplastic or non-paraneoplastic encephalitides and antibodies against both neural surface antigens (voltage-gated potassium channel-complexes, N-methyl-D-aspartate receptors) and intracellular antigens (glutamic acid decarboxylase-65), constitute an increasingly recognized group of immune-mediated brain diseases. Evidence for specific immune mechanisms, however, is scarce. Here, we report qualitative and quantitative immunopathology in brain tissue (biopsy or autopsy material) of 17 cases with encephalitis and antibodies to either intracellular (Hu, Ma2, glutamic acid decarboxylase) or surface antigenic targets (voltage-gated potassium channel-complex or N-methyl-D-aspartate receptors). We hypothesized that the encephalitides with antibodies against intracellular antigens (intracellular antigen-glutamic acid decarboxylase groups) would show neurodegeneration mediated by T cell cytotoxicity and the encephalitides with antibodies against surface antigens would be antibody-mediated and would show less T cell involvement. We found a higher CD8/CD3 ratio and more frequent appositions of granzyme-B + cytotoxic T cells to neurons, with associated neuronal loss, in the intracellular antigen-onconeural group (anti-Hu and anti-Ma2 cases) compared to the patients with surface antigens (anti-N-methyl-D-aspartate receptors and anti-voltage-gated potassium channel complex cases). One of the glutamic acid decarboxylase antibody encephalitis cases (intracellular antigen-glutamic acid decarboxylase group) showed multiple appositions of GrB-positive T cells to neurons. Generally, however, the glutamic acid decarboxylase antibody cases showed less...
Cytotoxic T cell and humoral inflammation in chronic encephalitides

Introduction

In recent years the spectrum of chronic inflammatory brain diseases characterized by the presence of antigen-specific antibodies in serum and CSF has greatly expanded. More and more, cases such as glutamic acid decarboxylase (GAD)-65 antibody encephalitis (Malter et al., 2010), voltage-gated potassium channel (VGKC) complex antibody encephalitis (Irani et al., 2010a), N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis (Dalmau et al., 2008) or the most recent α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (Lai et al., 2009) or gamma aminobutyric acid receptor GABA(B) antibody encephalitides (Lancaster et al., 2010) are recognized. In clinico-topological terms, the entities are designated as limbic encephalitis, cerebellar degeneration, brainstem encephalitis or encephalomyelitis. Furthermore, these syndromes can be grouped into paraneoplastic and non-paraneoplastic conditions. Paraneoplastic syndromes have received much of the attention since their conceptualization in the mid-20th century. Approximately 60% of patients with these syndromes have serum and CSF antibodies to intracellular antigens, often even intranuclear antigens such as Hu, Ma, Yo or amphiphysin (Saiz et al., 1999; Graus et al., 2001; Dalmau and Rosenfeld, 2008). A certain number of these paraneoplastic cases, however, have antibodies against surface antigens such as the NMDAR (Dalmau et al., 2011), the metabotropic glutamate receptor 1 (Dalmau and Rosenfeld, 2008; Lai et al., 2009; Lancaster et al., 2011) or the metabotropic glutamate receptor 5 (Lancaster et al., 2011).

The clinical syndromes are important entry points for the diagnostic work-up of patients, and the detection of a potential underlying cancer may be essential for a patient’s prognosis quo ad vitam. It has been suggested, however, that the most important determinant of the underlying immunopathogenesis and responsiveness to immunosuppression is the antibody status of the affected individual, which may determine the response to treatment (Dalmau and Rosenfeld, 2008; Graus et al., 2010; Vincent et al., 2010). Specifically, striking differences have been suggested between disorders with intracellular antigens versus those with antibodies to neural surface antigens. Disorders with antibodies to intracellular antigens are considered poorly responsive to immunotherapy (Vincent et al., 1999; Dalmau and Rosenfeld, 2008; Malter et al., 2010) and may be mediated by cytotoxic T cells (Bernal et al., 2002; Dalmau and Rosenfeld, 2008). Therefore, although of diagnostic importance, the antibodies against intracellular antigens are considered an immunological epiphenomenon (Dalmau and Rosenfeld, 2008; Graus et al., 2010). On the other hand, disorders associated with surface antigens, such as encephalitis with antibodies to the VGKC-complex or NMDAR, often respond well to treatment (Vincent et al., 2004; Malter et al., 2010; Dalmau et al., 2011) and may be mediated by antibody-binding, internalization and loss of the target surface antigens (Hughes et al., 2010). But many questions remain unresolved. For instance, why do patients with antibodies to the VGKC-complex, despite clinical improvements in mental function and often complete seizure control, develop medial temporal lobe and sometimes more global, atrophy (Vincent et al., 2004; Soeder et al., 2005)? Why is this atrophy not seen or is reversible in patients with NMDAR antibodies, despite their often devastating primary illness and frequent association with ovarian teratomata (Iizuka et al., 2010; Dalmau et al., 2011)? Furthermore, how does one classify patients with GAD antibodies directed to an intracellular antigen, but usually not paraneoplastic in origin, who suffer from limbic encephalitis or chronic temporal lobe epilepsy (Malter et al., 2010)?

Immunopathological analysis of the various antibody-associated encephalitides may help to elucidate the underlying immunopathogenetic mechanisms, but unfortunately the published studies are scarce, there is a lack of quantitative data and, to date, there are no studies correlating brain immunopathology with antibody status. Here, rather than comparing paraneoplastic with non-paraneoplastic encephalitides, we first investigated the hypothesis that cases with intracellular antigen antibodies show a different immune reaction than that of cases with surface antigen antibodies (Vincent et al., 1999; Dalmau and Rosenfeld, 2008; Graus et al., 2010). More specifically, we sought evidence that T cells

Keywords: encephalitis; antibodies; pathogenic; cytotoxic T lymphocytes; complement

Abbreviations: CASPR2 = contactin-associated protein-2; GAD = glutamic acid decarboxylase; GrB = granzyme-B; IAg = intracellular antigen; LGI1 = leucin-rich, glioma inactivated protein-1; MAP2 = microtubule associated protein-2; MHC = major histocompatibility complex; NeuN = neuronal nuclei; NMDAR = N-methyl-D-aspartate receptor; TUNEL = terminal deoxynucleotidyl transferase dUTP nick end labelling; VGKC = voltage-gated potassium channel

intense inflammation and also had relatively low CD8/CD3 ratios compared with the intracellular antigen-onconeural cases. Conversely, we found complement C9neo deposition on neurons associated with acute neuronal cell death in the surface antigen group only, specifically in the voltage-gated potassium channel-complex antibody patients. N-methyl-D-aspartate receptors-antibody cases showed no evidence of antibody and complement-mediated tissue injury and were distinguished from all other encephalitides by the absence of clear neuronal pathology and a low density of inflammatory cells. Although tissue samples varied in location and in the stage of disease, our findings strongly support a central role for T cell-mediated neuronal cytotoxicity in encephalitides with antibodies against intracellular antigens. In voltage-gated potassium channel-complex encephalitis, a subset of the surface antigen antibody encephalitides, an antibody- and complement-mediated immune response appears to be responsible for neuronal loss and cerebral atrophy; the apparent absence of these mechanisms in N-methyl-D-aspartate receptors antibody encephalitis is intriguing and requires further study.
would play a cytotoxic role in the cases with intracellular antigen antibodies, and that antibody and/or complement-mediated mechanisms are responsible for neurodegeneration in encephalitides with surface antigen antibodies. Secondly, we thoroughly analysed and compared the immunopathology of tissue from patients with GAD, VGKC-complex and NMDAR antibodies. Our results reveal that paraneoplastic cases with antibodies to intracellular antigens, as well as the non-paraneoplastic GAD65 cases, show signs of a T cell-mediated immune response. In the VGKC-complex cases with antibodies to surface antigens, we found antibody- and complement-mediated destruction of neurons. Finally, the NMDAR cases showed neither a cytotoxic T cell attack nor indication of complement-mediated neuronal damage. Clinically, our results may help to rationalize immunological treatment choices for these disorders.

**Materials and methods**

**Patients**

Paraffin-embedded brain specimens of 17 patients were studied. Individual patients are labelled according to the respective antibody and number (Hu/1, Hu/2, Hu/3, etc.). The specimens were obtained between 1991 and 2009 during autopsy (n = 6), epilepsy surgery (n = 5), diagnostic open brain biopsy (n = 5) or diagnostic stereotactic brain biopsy (n = 1). Biopsy sites were chosen according to normal areas on brain MRI. In patients with anti-NMDAR encephalitis (who all had normal MRI), the biopsy site chosen was based on maximal EEG abnormalities (as in Patient NMDAR1) or (in cases with diffusely abnormal EEG) by neurosurgical considerations in the right frontal convexity. Mean disease duration at specimen collection was 21 months (SD ± 37 months). Epilepsy surgery procedures were aimed at resection of the hypothesized epileptogenic area.

Serum antibodies were determined by standard methods (Vedeler et al., 2006) using a combination of immunohistochemistry and blot techniques. For GAD and NMDAR antibodies, titration of indirect immunohistochemistry, and for VGKC-complex antibodies radioimmunoassay with 125I-labelled dendrotoxin-VGKC-complexes, was used to quantify antibody concentration. From 2/4 VGKC-complex antibody *patients, serum for leucin-rich, glioma inactivated protein-1 (LG1) and contactin-associated protein-2 (CASPR2) antibody subtyping was available when these antibody tests were established (Irani et al., 2010a). No quantitative data were obtained for onconeural antibodies and LG1/CASPR2 antibodies. Patients harboured antibodies to the following antigens: Hu (n = 4), Ma2 (n = 3), GAD (n = 3), VGKC-complex (n = 4, in one directed to LG1, in one neither directed to LG1 nor to CASPR2) and NMDAR (n = 3).

Here we divided our patients into three groups. An intracellular antigen (IAg)-onconeural group which consists of the anti-Hu and anti-Ma2 cases, an IAg-GAD group, which holds the three non-paraneoplastic anti-GAD cases, and a surface antigen group, which contains both the anti-NMDAR and anti-VGKC cases. Demographic and paraclinical data of the individual patients are presented in Table 1. As positive controls for a specific cytotoxic T cell reaction, we studied 22 cases of Rasmussen encephalitis (Bien et al., 2002; Bauer et al., 2007; Schwab et al., 2009). In addition, we used neurodegenerative controls; 15 cases of Ammon’s horn sclerosis in patients operated on for mediotemporal epilepsy (Wieser and ILAE commission on neurosurgery for epilepsy, 2004), five cases of Alzheimer disease and five cases of acute cerebral hypoxia. Finally, autopsy controls without known neurological disease (n = 7) were included. For evaluation of NMDAR density, we compared biopsies from patients with anti-NMDAR encephalitis to surgical specimens from five patients with non-lesional epilepsy (temporal and extratemporal specimens). For immunoglobulin and C9neo deposition we used spinal cord sections of a patient with neuromyelitis optica with anti-aquaporin-4 antibodies as positive control.

**Histochemistry and immunohistochemistry**

Sections (4 μm) of paraffin embedded specimens were routinely stained with haematoxylin and eosin, Nissl stain for neurons and Luxol fast blue for myelin. Immunohistochemical staining and confocal fluorescence double staining were performed according to previously published protocols (Bien et al., 2002; Bauer et al., 2007) using the primary antibodies listed in Supplementary Table 1. As a first step, a qualitative assessment of the basic pathology, aimed at identifying the cell types (neurons, astrocytes, oligodendrocytes) that are lost or damaged, was undertaken. Immune reactions within tissues were then studied by both qualitative and quantitative methods using markers that identify inflammatory cells (T cells, B cells, plasma cells, macrophages and microglia), immunoglobulins, complement and major histocompatibility complex (MHC) molecules. For the CD3, CD8, MHC class I and Grb stainings, biotinylated tyramine enhancement was used as described previously (Bien et al., 2002).

**Confocal laser fluorescence microscopy**

Fluorescence immunohistochemistry was performed on paraffin sections as described for light microscopy with few modifications. For confocal fluorescent double labelling with primary antibodies from different species, antibodies were applied simultaneously at 4 °C overnight. After washing with Dako washing buffer (DakoCytomation), secondary antibodies consisting of donkey anti-mouse Cy3 (Jackson ImmunoResearch, 1:200) and biotinylated donkey anti-rabbit (Amersham Pharmacia Biotech; 1:200) were applied simultaneously for 1 h at room temperature, followed by application of streptavidin-Cy2 (Jackson ImmunoResearch; 1:75) or Cy2 at 1 h at room temperature. Fluorescent preparations were then stained with 4′,6′-diamidino-2-phenylindole (DAPI, Sigma), embedded and examined using a confocal laser scan microscope (Leica SP5) equipped with lasers for 504, 488, 543 and 633 nm excitation. Scanning for DAPI (504 nm), Cy2 (488 nm) and Cy3 (543 nm) was performed sequentially to rule out fluorescence bleed-through.

**Assessment of cell loss**

Chronic cell loss was qualitatively assessed in microtubule associated protein-2 (MAP2)/neuronal nuclei (NeuN) stained sections. The presence of axonal spheroids and excessive neuronal cytoplasmic accumulation of amyloid precursor protein (suggesting disruption of axonal protein transport) was qualitatively assessed by amyloid precursor protein immunostaining. Brain MRIs, which were available in 10/17 patients, were visually evaluated for signs of tissue loss.

**TUNEL**

In order to detect cells with DNA fragmentation, terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) was performed...
Table 1 Demographic data of the patients

<table>
<thead>
<tr>
<th>Patient</th>
<th>Gender</th>
<th>Age (a)</th>
<th>Antibody directed to (antibodies tested)</th>
<th>Tumour</th>
<th>Clinical syndrome</th>
<th>Disease duration (months)</th>
<th>Cause of death</th>
<th>Immunotreatment prior to specimen collection</th>
<th>CSF (i) Time to brain tissue collection</th>
<th>Specimen collection</th>
<th>Tissues</th>
<th>Brain atrophy on follow-up brain MRI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>IAg-onconeural group (intracellular antigen antibodies)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Ma2/1   | F      | 71      | Ma2 (onco, GAD) | Adeno- carcinoma lung | PEM     | 7                      | Death 1 week after seizure series | Plasma exchange briefly | g) −5 mo  
  (i) 4/μl  
  (ii) 0.83 g/l  
  (iv) Negative | Autopsy | Brainstem, hippocampus, cerebellum |
|         |        |         |                                       |        |                  |                          |                |                                             |                                      |                  |         |                                   |
| Ma2/2   | M      | 36      | Ma2 (onco) | Testicular carcinoma | PLE     | 1                      | –                       | None          | g) −1 mo  
  (ii) 9/μl  
  (iv) Negative | Stereotactic biopsy | Entorhinal cortex, Yes, mediotemporal (Fig. 1) |
|         |        |         |                                       |        |                  |                          |                |                                             |                                      |                  |         |                                   |
| Ma2/3   | M      | 34      | Ma2 (onco) | Testicular carcinoma | PLE     | 9                      | –                       | None          | g) −2 mo  
  (ii) 15/μl  
  (iv) Positive | Epilepsy surgery | Hippocampus, n.a. |
|         |        |         |                                       |        |                  |                          |                |                                             |                                      |                  |         |                                   |
| Hu/1    | M      | 65      | Hu (onco) | SCLC | PEM     | 13                     | n.a.                    | Unknown        | n.a.                                      | Autopsy | Basal ganglia, cerebellum |
|         |        |         |                                       |        |                  |                          |                |                                             |                                      |                  |         |                                   |
| Hu/2    | M      | 58      | Hu (onco) | Oatcell carcinoma lung | PEM     | 2.5                    | Progression of neurological syndrome, infectious complications and death from sepsis | Plasma exchange 1 month before death | g) −3 mo  
  (ii) 0  
  (iv) n.a. | Autopsy | Brainstem |
|         |        |         |                                       |        |                  |                          |                |                                             |                                      |                  |         |                                   |
| Hu/3    | M      | 49      | Hu (onco) | Adeno carcinoma prostatica | PEM     | 1.5                    | Progression of neurological syndrome, infectious complications and death from sepsis | 3/4 within 1 month prior to death | g) −10 days  
  (ii) 20/μl  
  (iv) n.a. | Autopsy (as Hu/2) | Medulla oblongata, n.a. |
|         |        |         |                                       |        |                  |                          |                |                                             |                                      |                  |         |                                   |
| Hu/4    | F      | 53      | Hu (onco) | Oatcell carcinoma lung | PEM     | 11                    | Progression of neurological syndrome, infectious complications and death from sepsis | 3/4 within 1 month prior to death | g) −5 mo  
  (ii) 0.45  
  (iv) N.a. | Autopsy (as Hu/2) | Cortex, n.a. |
| Summary, means ± SD |        | 2/7 F | 4 Hu, 3 Ma2 | | | 6 ± 4 | | | | | |
|         |        |         | IAg-GAD group (GAD antibodies) |        |                  |                          |                |                                             |                                      |                  |         |                                   |
| GAD/1   | F      | 18      | GAD 1:16 000 (onco, GAD, VGKC) | None | LE    | 127                   | –                       | None          | g) 10 years  
  (ii) 1/μl  
  (iv) positive | Epilepsy surgery | Hippocampus, n.a. |
|         |        |         |                                       |        |                  |                          |                |                                             |                                      |                  |         |                                   |
| GAD/2   | M      | 31      | GAD 1:1000 (onco, GAD) | None | LE    | 115                   | –                       | None          | g) 20 days  
  (ii) 25/μl  
  (iv) Negative | Epilepsy surgery | Hippocampus, Yes, mediotemporal |
|         |        |         |                                       |        |                  |                          |                |                                             |                                      |                  |         |                                   |
| GAD/3   | F      | 24      | GAD 1:32 000 (onco, GAD, VGKC) | None | LE    | 7                     | –                       | None          | g) 1 mo  
  (ii) 10/μl  
  (iv) Positive | Epilepsy surgery | Hippocampus, Yes, mediotemporal (Fig. 1) |

(continued)
Table 1 Continued

<table>
<thead>
<tr>
<th>Patient</th>
<th>Gender</th>
<th>Age</th>
<th>Antibody directed to (antibodies tested)</th>
<th>Tumour</th>
<th>Clinical syndrome</th>
<th>Disease duration (months)</th>
<th>Cause of death</th>
<th>Immunotreatment prior to specimen collection</th>
<th>CSF (i) Time to brain tissue collection (ii) Cell count (iii) Protein (iv) Unmatched oligoclonal bands</th>
<th>Specimen collection</th>
<th>Tissues</th>
<th>Brain atrophy on follow-up brain MRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summary, means ± SD</td>
<td>2/3 F</td>
<td>24 ± 5</td>
<td>3 GAD</td>
<td>None</td>
<td>None</td>
<td>83 ± 54</td>
<td>0/3</td>
<td>(i) 41 ± 56 mo (ii) 12 ± 10 ml, abnormal 2/3 (iii) 0.56 ± 0.26 g/l, abnormal 1/3 (iv) 2/3 positive</td>
<td>2/3 yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SAg group (surface antigen antibodies)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VGKC/1 (Case 10 in Vincent et al. (2004))</td>
<td>56</td>
<td></td>
<td>VGKC 2229 pmol/l; LG1, CASPR2 (onco, GAD, VGKC)</td>
<td>None</td>
<td>LE</td>
<td>8</td>
<td>None</td>
<td>(i) – 2 wks (ii) 6 µl (iii) 0.51 g/l (iv) Negative</td>
<td>Open biopsy</td>
<td>Uncus</td>
<td>Yes, global with mediotemporal accentuation (Fig. 1)</td>
<td></td>
</tr>
<tr>
<td>VGKC/2</td>
<td>M 59</td>
<td></td>
<td>VGKC 998 pmol/l; LG1, CASPR2 antibody status unknown (VGKC)</td>
<td>None</td>
<td>LE</td>
<td>5</td>
<td>Acute bronchopneumonia</td>
<td>(i) – 2 mo (ii) 0 (iii) 0.52 (iv) n.d.</td>
<td>Autopsy</td>
<td>Hippocampus</td>
<td>n.a.</td>
<td></td>
</tr>
<tr>
<td>VGKC/3</td>
<td>M 33</td>
<td></td>
<td>VGKC 167 pmol/l; LG1, CASPR2 (onco, VGKC)</td>
<td>None</td>
<td>Multifocal encephalitis</td>
<td>9</td>
<td>None</td>
<td>(i) – 2 wks (ii) 18 µl (iii) 0.71 g/l (iv) Positive</td>
<td>Open biopsy</td>
<td>Uncus</td>
<td>Yes, global (Fig. 1)</td>
<td></td>
</tr>
<tr>
<td>VGKC/4</td>
<td>F 68</td>
<td></td>
<td>VGKC 288 pmol/l; LG1, CASPR2 antibody status unknown (onco, GAD, VGKC)</td>
<td>None</td>
<td>LE</td>
<td>8</td>
<td>–</td>
<td>(i) 4 mo (ii) 2 µl (iii) 0.33 g/l (iv) n.d.</td>
<td>Epilepsy surgery</td>
<td>Amygdala</td>
<td>n.a.</td>
<td></td>
</tr>
<tr>
<td>NMDAR/1 (Nehusmann et al., 2009)</td>
<td>M 22</td>
<td></td>
<td>NMDAR 1:500 (onco, None GAD, VGKC, NMDAR)</td>
<td>Encephalopathy</td>
<td>2</td>
<td>–</td>
<td>None</td>
<td>(i) 18 mo (ii) 1 µl (iii) 0.29 g/l (iv) Negative</td>
<td>Open biopsy</td>
<td>Temporal neocortex</td>
<td>No (Fig. 1)</td>
<td></td>
</tr>
<tr>
<td>NMDAR/2 (Nehusmann et al., 2009)</td>
<td>F 17</td>
<td></td>
<td>NMDAR 1:2000 (onco, GAD, VGKC, NMDAR)</td>
<td>Encephalopathy 12 (from onset of first disease bout 2.2 mo after onset of first relapse)</td>
<td>1 week course of dex-amethasone 1 mo before biopsy</td>
<td>(i) – 4 mo (ii) 15 µl (iii) 0.19 g/l (iv) Positive</td>
<td>Open biopsy</td>
<td>Frontal lobe</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NMDAR/3</td>
<td>F 26</td>
<td></td>
<td>NMDAR 1:2000 (onco, GAD, VGKC, NMDAR)</td>
<td>Encephalopathy</td>
<td>11</td>
<td>–</td>
<td>60 mg prednisone and 150 mg azathioprin at time of biopsy</td>
<td>(i) – 24 days (ii) 13 µl (iii) 0.31 g/l (iv) Positive</td>
<td>Open biopsy</td>
<td>Frontal lobe</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Summary, means ± SD</td>
<td>3/7 F</td>
<td>40 ± 19</td>
<td>VGKC, 3 NMDAR</td>
<td></td>
<td></td>
<td>9 ± 6</td>
<td>2/6</td>
<td>(i) 1.0 ± 1.8 mo (ii) 7 ± 7 µl, abnormal 3/6 (iii) 0.39 ± 0.17 g/l, abnormal 2/6 (iv) 3/6 positive</td>
<td>VGKC: 3/3 NMDAR: 0/3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control groups</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rasmussen encephalitis, n = 22</td>
<td>13/22 F</td>
<td>16 ± 12</td>
<td>n.a.</td>
<td>None</td>
<td>None</td>
<td>53 ± 33</td>
<td>n.a.</td>
<td>Epilepsy surgery (n = 9), biopsy (n = 13)</td>
<td>Temporal (n = 15), extra-temporal (n = 7)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continued)
with the In Situ Cell Death Detection Kit (alkaline phosphatase) from Roche. Briefly, 3–5 μm paraffin sections were deparaffinized, treated with chloroform and air dried. Next, sections were treated with 0.1% protease for 30 min at 37°C. This was followed by incubation with labelled dUTP in the presence of terminal transferase according to the manufacturer's guidelines. Sections were developed with fast blue. Subsequently, the sections were stained with MAP2 or NeuN, or a mixture of both, followed by horseradish peroxidase-conjugated anti-mouse as a secondary system. This staining was developed with amino-ethyl carbazole as substrate. As a result, DNA fragmentation in the nucleus appears blue while MAP2/NeuN proteins appear red.

Quantification of parenchymal CD3 + , CD8 + , granzyme-B (GrB) + , CD20 + , CD138 + and CD68 + cells in tissue regions exhibiting inflammation on haematoxylin and eosin-stained sections was performed in consecutive sections using an ocular morphometric grid covering an area of 1 mm² at 100 (GrB + cells were assessed at 400 to be able to see the small granular signal). Scoring was performed by an experienced blinded observer (J.B.). The evaluated areas had a mean size of 10.8 mm² [range 0.5 mm² (in the only stereotactically obtained specimen, Patient 5)—50.0 mm²] per specimen. The CD8/CD3 ratio in the parenchyma we also calculated the ratio in the perivascular space of blood vessels. For this, we counted the number of CD3 and CD8 T cells (on average 24200 cells) in blood vessels of consecutive sections. In addition to the CD8/CD3 ratio in the parenchyma we also calculated the ratio in the perivascular space of blood vessels. For this, we counted the number of CD3 and CD8 T cells (on average 24200 cells) in blood vessels of consecutive sections.

Statistics

For metric data, a Kruskal–Wallis followed by Dunn's Multiple Comparisons Test was used. For metric data, Fisher's exact test was used. A p-value of <0.05 was considered significant. All tests were performed with Graphpad 5.0 (GraphPad Software, Inc.).

Results

Brain specimens

We studied brain material of 17 patients (10 male, 7 female, 17–71 years old). In Table 1, the clinical diagnoses, associated tumours and site of the specimens were grouped according to the antibody status [Hu (n = 4) or Ma2 (n = 3), GAD (n = 3), VGKC-complex (n = 4) or NMDAR (n = 3)] of the patient. In one patient, the respective sections were not available. This case with anti-Ma2 limbic encephalitis (Patient 6) was not included in the study.

Quantification of cells

Table 1

<table>
<thead>
<tr>
<th>Patient</th>
<th>Gender</th>
<th>Age</th>
<th>Antibody directed to (antibodies tested)</th>
<th>Tumour</th>
<th>Clinical syndrome</th>
<th>Disease duration (months)</th>
<th>Cause of death</th>
<th>Immunochemical treatment prior to specimen collection</th>
<th>CSF collection</th>
<th>Specimen collection</th>
<th>Tissues</th>
<th>Brain atrophy on follow-up Brain MRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>(AHS, n = 15; Alzheimer, n = 5, acute hypoxia, n = 5)</td>
<td>Normal controls, n = 7</td>
<td>3/7 F</td>
<td>n.a.</td>
<td>None</td>
<td>–</td>
<td>n.a.</td>
<td>n.a.</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>(Alzheimer, n = 5, acute hypoxia, n = 5)</td>
<td>3/7 F</td>
<td>59 ± 10</td>
<td>n.a.</td>
<td>None</td>
<td>–</td>
<td>n.a.</td>
<td>n.a.</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Table 1 Continued

<table>
<thead>
<tr>
<th>Patient</th>
<th>Gender</th>
<th>Age</th>
<th>Antibody directed to (antibodies tested)</th>
<th>Tumour</th>
<th>Clinical syndrome</th>
<th>Disease duration (months)</th>
<th>Cause of death</th>
<th>Immunochemical treatment prior to specimen collection</th>
<th>CSF collection</th>
<th>Specimen collection</th>
<th>Tissues</th>
<th>Brain atrophy on follow-up Brain MRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>(AHS, n = 15; Alzheimer, n = 5, acute hypoxia, n = 5)</td>
<td>Normal controls, n = 7</td>
<td>3/7 F</td>
<td>n.a.</td>
<td>None</td>
<td>–</td>
<td>n.a.</td>
<td>n.a.</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>(Alzheimer, n = 5, acute hypoxia, n = 5)</td>
<td>3/7 F</td>
<td>59 ± 10</td>
<td>n.a.</td>
<td>None</td>
<td>–</td>
<td>n.a.</td>
<td>n.a.</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

a With references to papers in which cases has been included previously.
b Age and disease durations were not significantly different between the IAg-onconeural, IAg-GAD and surface antigen group. The following CSF parameters were considered abnormal: cell count >5/μl, protein content >0.5 g/l. Means ± SD.

AHS = Ammon’s horn sclerosis; IVIG = intravenous immunoglobulins; IVMP = intravenous methylprednisolone; LE = limbic encephalitis; mo = months; PEM = paraneoplastic encephalomyelitis; PLE = paraneoplastic limbic encephalitis; SCLC = small cell lung carcinoma; n.a. = not applicable; F = female; M = male.
Ma2/2) showed progressive atrophy of the T2/FLAIR-hyperintense mediotemporal lobe (Fig. 1). In two out of three anti-GAD cases with limbic encephalitis, mediotemporal atrophy in the context of T2/FLAIR hyperintensity developed during the disease course. The third patient had previously had unilateral encephalitic T2-hypersignal in the left amygdala, but at the time of epilepsy surgery, MRI was normal and without mediotemporal brain atrophy, despite a 10-year disease history. In both patients with VGKC-complex antibodies and serial brain MRIs, brain atrophy developed in areas of encephalitic T2/FLAIR-hypersignal (Fig. 1).
Neuronal pathology

Neuronal cell loss was seen on MAP2/NeuN stained sections in five out of seven IAgs-onconeural cases, two out of three IAgs-GAD cases and one out of seven surface antigen (VGKC-complex) cases (Fig. 2A, C, E, H and K). The most severe neuronal loss was found in one anti-Hu, one anti-Ma2, one anti-GAD and one anti-VGKC-complex case. TUNEL reactivity revealed that most cases only had limited (occasional cells) acute neuronal death, but a single autopsy case (Patient VGKC/2), showed numerous TUNEL + neurons in the CA4 region and dentate gyrus of the hippocampus (Fig. 3H and I). In addition, most of the tissue from those patients showed axonal damage demonstrated by amyloid precursor protein positive spheroids and accumulation of amyloid precursor protein in the cell bodies of neurons (Fig. 2B, D, F, G, I, J and L). In contrast, in all three anti-NMDAR biopsy cases, pathological evidence of neuro-axonal injury was notably absent.

Histochemical staining for Luxol fast blue and immunohistochemistry for 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) and proteolipid protein did not reveal loss of oligodendrocytes or evidence of demyelination, and staining for glial fibrillary acidic protein did not reveal astrocyte loss, in either group.

Immunopathology

Inflammation

We quantified the numbers of parenchymal T cells, B cells, plasma cells, macrophages and microglial cells. The results are given for the individual patients in Table 2, and summarized in Table 3. Overall, there was a large variation in the absolute numbers of CD3+ T cells (1.2–1188/mm²) between the individual specimens (Tables 2 and 3). However, in one of the three biopsies from the IAgs-GAD patients and all three biopsies of NMDAR antibody+ patients, the density of parenchymal infiltrating CD3+ T cells was low, within the range of neurodegeneration controls, although still higher than that of the healthy controls (Table 2). Density of inflammatory cells in all anti-NMDAR cases was lower than in the other groups, although T cell numbers exceeded those observed in normal controls and were in the range of the neurodegeneration controls (Table 3).

T cell cytotoxicity

In all specimens, CD3+ lymphocytes comprised the majority of parenchyma invading inflammatory cells (Table 3; Figs 3A, D, 4A, D and G). There was a clear difference in the percentage of parenchymal CD8+ T cells (ratio CD8/CD3) between IAgs-onconeural (mean 75%, Figs 4B, E, H and 5) and surface antigen (mean 43%, Figs 3B, E and 5) cases (P < 0.05). The percentage of CD8 T cells in the IAgs-GAD group was intermediate (54%) between the IAgs-onconeural and surface antigen groups and not significantly different from both groups. The CD8/CD3 ratio of the surface antigen group also was significantly different from both IAgs-onconeural (mean 43%, Figs 3B, E and 5) and surface antigen (mean 75%, Figs 4B, E, H and K) cases (P < 0.05). For comparison, we also determined the CD8/CD3 ratio in the perivascular space of blood vessels. Generally in a specific patient the ratio was lower than in the parenchyma (Table 2) confirming that generally CD8 T cells migrate into the parenchyma more readily than CD4 T cells. Unexpectedly, however, the perivascular CD8/CD3 ratio in the NMDAR antibody patients was higher than those in the corresponding parenchyma. These results are based on single immunostainings with CD3 and CD8 on consecutive sections, but were confirmed on sections double-labelled for CD4 and CD8 (Figs 3G and 4I). In addition, we determined the percentage of GrB+/CD3+ cells. There was a high GrB percentage in the IAgs-onconeural group compared with the IAgs-GAD and surface antigen groups, but no significant difference between the different groups was reached (Fig. 5). In all respects, the IAgs-onconeural specimens were very similar to those found in the Rasmussen encephalitis control group in which T cell cytotoxicity is well established (Bien et al., 2002).

Apposition of multiple GrB+ lymphocytes to single neurons, consistent with a specific cytotoxic T cell attack, was observed in five of seven IAgs-onconeural cases (Fig. 4C, F, J–L), and in one of the IAgs-GAD cases (Patient GAD/3). The amount of multiple apposition in the IAgs-onconeural group was higher than those seen in the surface antigen group in which no multiple appositions were detected (IAgs-onconeural versus surface antigen group: P = 0.02, two-sided Fisher’s exact test, Fig. 3C, F and Table 3). Again, the IAgs-onconeural group was similar (no significant difference) to the Rasmussen encephalitis control group in which 6 out of 22 showed such multiple appositions. In the IAgs-GAD group one out of three patients also showed such multiple appositions. The IAgs-GAD group did not show significant differences with both the IAgs-onconeural, the surface antigen group and the Rasmussen encephalitis specimens (Table 3). We also stained sections for CD107a (lysosomal-associated membrane protein-1, lamp-1), a marker that only appears on the cell surface of T lymphocytes after the release of cytotoxic granules (Betts et al., 2003). In areas where GrB+ lymphocytes were present, CD107a+ lymphocytes were also detected (Fig. 4M and N). In the IAgs-onconeural group, dual staining revealed punctuate reactivity for CD107a overlapping that of GrB within cytotoxic T lymphocytes (Fig. 4P and Q). In addition, CD107a also appeared to be fused with the membranes of some T lymphocytes in a polarized fashion (Fig. 4O), indicating release of cytotoxic granules from cells that were often found in close apposition to neurons. Occasionally, polarized CD107a was a notable finding in the absence of GrB, suggesting that GrB had been released previously (Fig. 4Q and R). These GrB and CD107a findings mirror the stages of a GrB-mediated cytotoxic T cell attack in vitro (Hahn et al., 1994; Betts et al., 2003) and suggest that a cytotoxic T cell mediated immune response is responsible for neuronal cell death in the IAgs-onconeural as well as in one of the three cases of the IAgs-GAD group. MHC class I expression is a necessary prerequisite for cytotoxic T cell mediated killing. We found expression of MHC class I on neurons in inflammatory sites in all groups (data not shown).

Immunoglobulin and complement deposition

Diffuse cytoplasmic IgG, detected with anti-human IgG, was evident in both neurons and astrocytes in most cases from all groups.
(Fig. 6), but similar anti-IgG staining patterns were also present in Rasmussen encephalitis and neurodegenerative control samples (data not shown). This diffuse cytoplasmic staining is likely to be the result of non-specific uptake of human immunoglobulin due to leakiness of (damaged) neuronal membranes (Barnett et al., 2009). In the spinal cord of a neuromyelitis optica autopsy control, parenchymal staining for immunoglobulin was seen (Fig. 6A). Strikingly, in anti-VGKC-complex encephalitis, but not in the other conditions, there was also evidence of immunoglobulin on the surface of neurons (Fig. 6K). Staining for C9neo, indicative of
functional activation of the complement cascade, was clearly seen in the parenchyma around blood vessels in the spinal cord of the case with neuromyelitis optica (Fig. 6B), as expected. C9neo was negative in all controls, all cases of the IAg-onconeural and IAg-GAD groups (Fig. 6D, F and H), and all three anti-NMDAR cases (Fig. 6J). However, C9neo deposition was clearly present in the cytoplasm and on the surface of hippocampal CA4 neurons, on neurons in the dentate gyrus and on cortical neurons (Fig. 6L and M) in three out of four anti-VGKC-complex cases. In the case with strongest C9neo deposition (Patient VGKC/2), this deposition co-localized with the TUNEL reactivity seen in MAP2 + neurons (Fig. 3H and I), demonstrating severe acute neuronal death.

**Discussion**

There is considerable interest in autoimmune forms of encephalitis associated with specific antibodies to neuronal proteins such as the onconeural antigens, VGKC-complex, NMDAR and GAD. It is generally considered that antibodies to intracellular antigens are good biomarkers for the associated diseases but that the pathology of these conditions is due to T cell cytotoxicity. In contrast, antibodies to the cell surface antigens, VGKC-complex proteins and NMDAR, are thought to be directly pathogenic. However, with the improved recognition and treatment of these patients,
Table 2 Individual data on quantitative immunopathology of patients and control groups

<table>
<thead>
<tr>
<th>Patient numbers</th>
<th>Number of specimens evaluated</th>
<th>CD3 (cells/mm²)</th>
<th>CD8 (cells/mm²)</th>
<th>CD8 (% of CD3 parenchymal)</th>
<th>CD8 (% of CD3 perivascular)</th>
<th>GrB (cells/mm²)</th>
<th>GrB (% of CD3)</th>
<th>GrB multiple appositions</th>
<th>CD20 (cells/mm²)</th>
<th>CD138 (cells/mm²)</th>
<th>Mac (cells/mm²)</th>
<th>Mic (cells/mm²)</th>
<th>Complement activation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patients with antibodies to intracellular antigens</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mu2/1</td>
<td>3</td>
<td>346.0</td>
<td>228.0</td>
<td>66</td>
<td>32</td>
<td>52.0</td>
<td>15</td>
<td>Yes</td>
<td>6.4</td>
<td>13</td>
<td>27.1</td>
<td>304.8</td>
<td>No</td>
</tr>
<tr>
<td>Mu2/2</td>
<td>2</td>
<td>1188.0</td>
<td>806.4</td>
<td>68</td>
<td>np</td>
<td>616.7</td>
<td>52</td>
<td>Yes</td>
<td>264.0</td>
<td>224.0</td>
<td>76.0</td>
<td>260.0</td>
<td>No</td>
</tr>
<tr>
<td>Mu2/3</td>
<td>1</td>
<td>90.4</td>
<td>81.3</td>
<td>90</td>
<td>65</td>
<td>19.8</td>
<td>22</td>
<td>No</td>
<td>0.0</td>
<td>1.0</td>
<td>0.0</td>
<td>55.5</td>
<td>No</td>
</tr>
<tr>
<td>Hu1</td>
<td>1</td>
<td>273.0</td>
<td>205.0</td>
<td>75</td>
<td>52</td>
<td>95.0</td>
<td>35</td>
<td>Yes</td>
<td>126.0</td>
<td>15.0</td>
<td>7.0</td>
<td>369.0</td>
<td>No</td>
</tr>
<tr>
<td>Hu2</td>
<td>1</td>
<td>12.3</td>
<td>7.8</td>
<td>63</td>
<td>37</td>
<td>4.0</td>
<td>33</td>
<td>No</td>
<td>0.0</td>
<td>1.4</td>
<td>3.0</td>
<td>60.0</td>
<td>No</td>
</tr>
<tr>
<td>Hu3</td>
<td>1</td>
<td>27.8</td>
<td>17.6</td>
<td>64</td>
<td>39</td>
<td>2.9</td>
<td>10</td>
<td>Yes</td>
<td>0.3</td>
<td>1.6</td>
<td>0.0</td>
<td>41.0</td>
<td>No</td>
</tr>
<tr>
<td>Hu4</td>
<td>1</td>
<td>396.0</td>
<td>384.0</td>
<td>97</td>
<td>67</td>
<td>132.0</td>
<td>33</td>
<td>Yes</td>
<td>0.4</td>
<td>1.0</td>
<td>0.0</td>
<td>398.0</td>
<td>No</td>
</tr>
<tr>
<td><strong>Patients with GAD antibodies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAD1</td>
<td>1</td>
<td>2.1</td>
<td>1.3</td>
<td>61</td>
<td>56</td>
<td>0.0</td>
<td>0</td>
<td>No</td>
<td>0.0</td>
<td>0.0</td>
<td>0.3</td>
<td>134.4</td>
<td>No</td>
</tr>
<tr>
<td>GAD2</td>
<td>1</td>
<td>7.5</td>
<td>3.9</td>
<td>52</td>
<td>49</td>
<td>0.0</td>
<td>0</td>
<td>No</td>
<td>0.1</td>
<td>0.0</td>
<td>0.6</td>
<td>212.8</td>
<td>No</td>
</tr>
<tr>
<td>GAD3</td>
<td>1</td>
<td>70.0</td>
<td>35.0</td>
<td>90</td>
<td>50</td>
<td>1.5</td>
<td>2</td>
<td>Yes</td>
<td>6.5</td>
<td>9.5</td>
<td>0.0</td>
<td>312.0</td>
<td>No</td>
</tr>
<tr>
<td><strong>Patients with antibodies to surface antigens</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VGKC1 (LG1 Abs)</td>
<td>1</td>
<td>5.9</td>
<td>3.1</td>
<td>53</td>
<td>np</td>
<td>0.0</td>
<td>0</td>
<td>No</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>147.2</td>
<td>Yes</td>
</tr>
<tr>
<td>VGKC2 (Ab specificity unknown)</td>
<td>1</td>
<td>13.2</td>
<td>7.0</td>
<td>53</td>
<td>41</td>
<td>4.0</td>
<td>31</td>
<td>No</td>
<td>0.2</td>
<td>0.0</td>
<td>0.6</td>
<td>98.0</td>
<td>Yes</td>
</tr>
<tr>
<td>VGKC3 (LG1/CASPR2 Ab-negative)</td>
<td>1</td>
<td>651.6</td>
<td>324.4</td>
<td>50</td>
<td>28</td>
<td>67.2</td>
<td>10</td>
<td>No</td>
<td>24.0</td>
<td>12.8</td>
<td>18.0</td>
<td>250.0</td>
<td>Yes</td>
</tr>
<tr>
<td>VGKC4 (Ab specificity unknown)</td>
<td>1</td>
<td>21.9</td>
<td>9.7</td>
<td>44</td>
<td>np</td>
<td>0.5</td>
<td>2</td>
<td>No</td>
<td>0.0</td>
<td>0.0</td>
<td>0.8</td>
<td>166.0</td>
<td>No</td>
</tr>
<tr>
<td>NMDAR1</td>
<td>1</td>
<td>2.8</td>
<td>0.6</td>
<td>23</td>
<td>63</td>
<td>0.0</td>
<td>0</td>
<td>No</td>
<td>2.1</td>
<td>0.8</td>
<td>2.9</td>
<td>129.6</td>
<td>No</td>
</tr>
<tr>
<td>NMDAR2</td>
<td>1</td>
<td>1.2</td>
<td>0.4</td>
<td>30</td>
<td>66</td>
<td>0.1</td>
<td>7</td>
<td>No</td>
<td>0.0</td>
<td>0.1</td>
<td>2.5</td>
<td>65.7</td>
<td>No</td>
</tr>
<tr>
<td><strong>Controls: means (ranges)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rasmussen encephalitis</td>
<td>22</td>
<td>19.5 (0.6–127.8)</td>
<td>16.1 (0.4–101.5)</td>
<td>81 (40–100)</td>
<td>ND</td>
<td>7.0 (0.0–42.3)</td>
<td>320–94</td>
<td>6/22 Yes</td>
<td>0.1 (0.0–0.5)</td>
<td>0.1 (0.0–1.6)</td>
<td>0.5 (0.0–5.3)</td>
<td>87.5 (4.0–283.3)</td>
<td>0/22 Yes</td>
</tr>
<tr>
<td>Neurodegeneration</td>
<td>25</td>
<td>1.9 (0.2–4.7)</td>
<td>1.2 (0.0–6.5)</td>
<td>58 (0–200)</td>
<td>ND</td>
<td>0.2 (0.0–1.0)</td>
<td>14 (0–67)</td>
<td>0/25 Yes</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–0.0)</td>
<td>0.2 (0.0–2.0)</td>
<td>100.0 (30.0–313.0)</td>
<td>0/25 Yes</td>
</tr>
<tr>
<td>Normal controls</td>
<td>7</td>
<td>0.1 (0.0–0.3)</td>
<td>0.1 (0.0–0.1)</td>
<td>17 (0–50)</td>
<td>ND</td>
<td>0.0 (0.0–0.1)</td>
<td>15 (0–36)</td>
<td>0/7 Yes</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–0.0)</td>
<td>43.6 (20.0–66.0)</td>
<td>0/7 Yes</td>
</tr>
</tbody>
</table>

Multiple appositions relate to neurons engulfed by more than one GrB+ T cell. 

Due to tyramine enhancement, in some samples a 20% increase in CD8+ cells was achieved. This enhanced sensitivity for CD8 together with small individual cell counts in the controls is reflected in occasional > 100% CD8/CD3 ratios. 

GrB = granzyme B; Mac = macrophages; Mic = microglial cells; np = not enough cells in blood vessels present to analyse; ND = not done.
biopsy and autopsy tissues are seldom available and the immunopathology of the conditions is not well studied. The few reports available have identified ‘T cell infiltrates’ and most did not attempt to define different T and B cell mediated mechanisms.

The clinical presentations of the disorders studied here are remarkably similar, usually consisting of a combination of neuropsychological impairment and seizures. On the other hand, the newly described encephalitides with antibodies to the VGKC-complex and NMDAR (i.e. surface antigens) have a much better clinical outcome (Thieben et al., 2004; Vincent et al., 2004; Dalmau et al., 2008; Irani et al., 2010b) than the classical paraneoplastic encephalitides associated with antibodies to intracellular antigens (Dalmau and Rosenfeld, 2008). This is particularly true in patients with VGKC-complex antibodies, and also in anti-NMDAR encephalitis in which removal of an underlying malignancy (usually ovarian teratoma) can be associated with excellent recovery; clinical outcomes in the patients without detectable tumours are less complete and some relapse (Irani et al., 2010a; Dalmau et al., 2011). These observations have resulted in a conceptual shift from a clinicoimmunological (limbic encephalitis), or paraneoplastic versus non-paraneoplastic approach, to an antibody-focused viewpoint with a particular emphasis on the distinction between antibodies to intracellular antigens versus surface antigens (Buckley and Vincent, 2005; Tuzun and Dalmau, 2007; Dalmau and Rosenfeld, 2008; Vincent et al., 2010).

Here we tested the hypothesis that encephalitides with intracellular antigens differ in their immune reaction from encephalitides with surface antigens, and that T cells would only play a cytotoxic role in the former group. In the IAg-onconeural group and the IAg-GAD group (non-paraneoplastic GAD cases) we found no evidence of IgG or complement deposition, but we found multiple appositions of GrB+ cytotoxic T cells to neurons, very similar to those previously described in patients with Rasmussen encephalitis (Bien et al., 2002; Bauer et al., 2007). Moreover, we found that the patients from the IAg-onconeural group had a higher CD8/CD3 ratio than patients with antibodies to surface antigens.

Previous studies in paraneoplastic encephalitis with onconeural antibodies suggested that neuronal damage is induced by a cytotoxic T cell mediated response, demonstrating the presence of T cell intracytoplasmic antigen-1-positive lymphocytes in the vicinity of neurons (Blumenthal et al., 2006). Here, we confirmed these observations and provide further evidence for GrB-mediated neuronal cytotoxicity showing both release of GrB and detection of CD107a on the surface of T cells. These findings mirror the stages of GrB-mediated cytotoxic T cell attack documented in vitro (Hahn et al., 1994; Betts et al., 2003).

The results of the IAg-GAD cases, however, were somewhat different from the paraneoplastic cases with intracellular antigen antibodies. Although not significant, the CD8/CD3 ratio in the GAD antibody+ cases was lower than those of the paraneoplastic cases, and within the range of the highest ratios of the surface antigen group. In addition, one of the three anti-GAD cases (Patient GAD/1) showed T cell numbers that were as low as those of the anti-NMDAR cases. This particular patient, however, did not develop atrophy on MRI, compatible with the hypothesis that T cells are relevant to, or perhaps requisite for, neuronal loss and the development of atrophy in patients with GAD antibodies. It remains a question why the T cell numbers and the CD8/CD3 ratio in these GAD patients are rather low compared to the other cases with antibodies against intracellular antigens. The absence of an underlying malignancy may be a reason, but also the long disease duration time in two patients may bias this result towards less intense inflammation. The syndrome of epilepsy and limbic encephalitis with GAD antibodies has only recently been studied.

### Table 3 Immune cells in encephalitis with antibodies to intracellular and surface antigens

<table>
<thead>
<tr>
<th>Demographic data</th>
<th>IAg-onconeural (n = 7)</th>
<th>IAg-GAD (n = 3)</th>
<th>Surface antigen (n = 7)</th>
<th>RE (n = 22)</th>
<th>Neurodegeneration (n = 25)</th>
<th>Normal controls (n = 7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at specimen collection (years)</td>
<td>52 ± 17</td>
<td>27 ± 31</td>
<td>40 ± 19</td>
<td>16 ± 12</td>
<td>47 ± 26</td>
<td>59 ± 10</td>
</tr>
<tr>
<td>Disease duration at specimen collection (months)</td>
<td>6 ± 4</td>
<td>83 ± 54</td>
<td>9 ± 6</td>
<td>53 ± 33</td>
<td>129 ± 190</td>
<td>n.a.</td>
</tr>
<tr>
<td>Inflammation</td>
<td>CD3 (cells/mm²)</td>
<td>333 ± 377</td>
<td>27 ± 31</td>
<td>100 ± 225</td>
<td>20 ± 29</td>
<td>1.9 ± 1.6</td>
</tr>
<tr>
<td>CD3</td>
<td>247 ± 259</td>
<td>13 ± 15</td>
<td>49 ± 112</td>
<td>16 ± 23</td>
<td>1.2 ± 1.5</td>
<td>0.1 ± 0.0</td>
</tr>
<tr>
<td>GrB</td>
<td>132 ± 203</td>
<td>0.5 ± 0.7</td>
<td>10 ± 23</td>
<td>7 ± 11</td>
<td>0.2 ± 0.3</td>
<td>0 ± 0</td>
</tr>
<tr>
<td>Cases with multiple appositions of GrB+ T cells to neurons</td>
<td>0/7</td>
<td>1/3</td>
<td>0/7</td>
<td>6/22</td>
<td>0/25</td>
<td>0/7</td>
</tr>
</tbody>
</table>

Cell densities are given as per mm² in 4 µm paraffin sections (means ± SD).

a Significantly different from the surface antigen group (test was only performed for comparison of IAg-onconeural, IAg-GAD, surface antigen and Rasmussen encephalitis groups).

n.a. = not applicable; RE = Rasmussen encephalitis.
Figure 4  Pathology of brains of encephalitides with antibodies to intracellular antigens. (A–C) Anti-Hu (paraneoplastic) encephalitis (Patient Hu/4). Staining for CD3 (A) and CD8 (B) show prominent perivascular and parenchymal infiltration of T cells. (C) Staining for GrB (arrows) shows multiple appositions of these cells to a neuron. Scale bars: A, B = 100 µm, C = 20 µm. (D–F) Anti-GAD encephalitis (Patient GAD/3). Multiple CD3⁺ cells (D) and CD8⁺ cells (E) are seen in the parenchyma. (F) Staining for GrB in this GAD case shows apposition of two cytotoxic T cells with polarized granules towards a neuron. Scale bars: (D and E) = 100 µm, (F) = 20 µm. (G–R) Anti-Ma-2 antibody (paraneoplastic) encephalitis (Patient Ma2/1). (G) Multiple neurons (arrowheads) are surrounded by multiple CD3⁺ T lymphocytes. (H) Staining for CD8 in the same area shows that these encircling T cells are also CD8⁺. Scale bars: (G and H) = 50 µm. (I) Double staining for CD4 (blue) and CD8 (red) shows that the larger part of T cells are CD8⁺. Scale bar: (I) = 50 µm. (J) Staining for GrB in the same area as (G) and (H) shows that several neurons (arrows) have multiple appositions of GrB⁺ cytotoxic T cells attached to them (same area as G and H). (K) Higher magnification of a neuron with multiple attached GrB⁺ T lymphocytes. Scale bar = 10 µm. (L) Another GrB⁺ T lymphocyte in close apposition to a neuron. In this case, GrB reactivity is seen on the neuronal membrane (arrowhead) indicating release of GrB from the T cell. Scale bar = 10 µm. (M and N) Two examples of lymphocytes attached to neurons. A polarized membranous CD107a staining is seen, indicating release of cytotoxic granules. Scale bars = 5 µm. (O) Confocal double staining for CD3 (red) and CD107a (green) shows a lymphocyte in apposition to a neuron [indicated by lipofuscin (LF)]. The signal for CD107a (arrowhead) overlaps with the staining for CD3 indicating fusion of cytotoxic granules with the membrane during release. The arrow shows CD107a in perineuronal microglia. In (P), a lymphocyte with GrB⁺ (red) granules in a non-polarized localization in apposition to a neuron (LF) is shown. The GrB signal overlaps with the signal for CD107a, indicating no release of GrB has taken place. Scale bar = 5 µm. (Q and R) Two examples of confocal double staining for GrB (red) and CD107a (green). (Q) A lymphocyte in which CD107a is colocalized with GrB (arrow). A second lymphocyte lies in apposition to a neuron and shows polarized membranous-like CD107a in the absence of GrB (arrowhead) indicating previous release of the cytotoxic compound. Scale bar = 10 µm. The same can be seen in (R). Again a CD107a⁺ /GrB⁺ T lymphocyte without polarization and a CD107a⁺ /GrB⁻ T lymphocyte (arrowhead) with polarization is shown in close apposition to a neuron. Scale bar = 10 µm.
Vincent, in preparation). Such an additional surface antigen antibodies have been observed (Chang and et al.). Patients with limbic encephalitis (Lancaster et al.) has been reported in a small number of patients with surface antigen antibodies coexisting with GAD antibodies (Vincent et al., 1995; Viglietta et al., 2002). On the other hand, however, GAD antibodies are seldom associated with malignancies and the benefits of immunotherapies, including intravenous immunoglobulins, have been demonstrated in case reports and in a randomized clinical trial (Dalakas et al., 2001) suggesting similarities with diseases associated with surface antigens, albeit with lesser treatment responses (Malter et al., 2010). The more frequent occurrence of unmatched oligoclonal bands in patients with GAD antibodies brings them closer to the surface antigen patients than to the IAg-onconeural patients (Table 1). One explanation for these observations could be the existence of pathogenic surface antigen antibodies coexisting with GAD antibodies (Vincent et al., 1999); indeed, coexistence of GAD and GABA-B receptor antibodies has been reported in a small number of patients with limbic encephalitis (Lancaster et al., 2010; Boronat et al., 2011). Also, in stiff person syndrome with GAD antibodies, additional cell-surface antibodies have been observed (Chang and Vincent, in preparation). Such an additional surface antigen antibody might be an alternative explanation for the relatively low CD8/CD3 and GrB/CD3 ratios in our IAg-GAD patients. Thus, although our findings support the hypothesis that encephalitis with intracellular antigen antibodies are mediated by cytotoxic T cells, this hypothesis may be too restricted since it does not take into account the possibility that multiple antibodies against both intracellular antigens, as well as surface antigens, exist in patients with GAD antibodies.

The second group that we investigated was the group with surface antigen antibodies. Intriguingly these two surface antigen antibody diseases differ strongly in terms of immunopathology. The neocortex of NMDAR antibody-positive patients showed almost no inflammation, and no clear signs of neuronal loss. By contrast, there was loss of neurons with evidence of IgG and complement deposition in the VGKC-complex antibody-positive cases. The distinction between cases with or without neuronal loss was reflected by MRI features, with atrophy restricted to patients with VGKC-complex antibodies. Consistent with our findings, Tüzün et al. (2009) found only rare infiltrating inflammatory cells and absence of complement in the brains of patients with anti-NMDAR encephalitis and hippocampal neuronal loss was detected in only one of four brains studied by Dalmau et al. (2008). Concordantly, follow-up MRI studies in many patients show absence of brain atrophy. Existing non-quantitative neuropathological evidence in anti-NMDAR encephalitis shows hippocampal pyramidal cell loss but only mild inflammation (Tüzün et al., 2009; Camdessanche et al., 2011). In our anti-NMDAR cases with neocortical samples only, we did not observe clear cell loss, signs of acute cell damage or atrophy on brain MRI. Furthermore there were few infiltrating T cells, their numbers were lower than in the other antibody-defined subgroups and in the range of neurodegenerative controls. In contrast to VGKC-complex antibody-positive cases, we found no evidence of complement activation, consistent with previous case reports (Tüzün et al., 2009; Hughes et al., 2010). Experimental evidence suggests that the NMDAR antibodies act by reducing the density of NMDAR clusters by cross-linking and subsequent internalization of the receptors, leading to a state of reversible NMDAR hypofunction (Hughes et al., 2010). Taken together, even though NMDAR antibodies appear to be involved in the clinical disease process, there is no evidence in favour of classical cytotoxic T cell-mediated or antibody and complement-mediated neuronal cell death in our cases. The possibility that a more active inflammatory infiltrate or antibody deposition could be found at an earlier disease stage in both the hippocampus and cortex, cannot be excluded, although it is striking that MRI evidence of inflammation in the hippocampus is rare in this condition. An exclusive effect of the antibodies in reducing NMDAR expression in the hippocampus, however, would be difficult to reconcile with the complex progression of the disease that begins with features which could stem from medial temporal lobe dysfunction but progresses to a much broader clinical phenotype (Dalmau et al., 2008; Irani et al., 2010b).

In the three previous VGKC-complex antibody autopsy case studies, which lacked the detail provided here, scattered T cell infiltration (Dunstan and Winer, 2006; Park et al., 2007) perivascular B cell accumulation and an intraparenchymal infiltrate with predominance of CD4+ T cells have been reported (Khan et al.,...
We found variably intense inflammation and overall a lower CD8/CD3 ratio than in the patients with antibodies to intracellular antigens. Although GrB+ T cells were present in the lesions we did not observe apposition of these cells to neurons or release of GrB, therefore T cell cytotoxicity in our view is not a major contributor. However, immunoglobulin and complement deposition on neurons was a prominent finding and TUNEL reaction in the same area demonstrated acute neuronal cell death. This suggests antibody and complement mediated neuronal cell damage in patients with VGKC-complex antibodies. This is interesting since IgG4 rather than complement-activating IgG1 antibodies dominate in sera of patients with VGKC-complex antibody encephalitis (unpublished data). Recent findings show that the antibodies that immunoprecipitate dendrotoxin-labelled VGKC-complexes are in fact directed to LGI1 or CASPR2 or other undefined components of the VGKC-complex (Irani et al., 2010a; Lai et al., 2010). One of our three cases with C9neo deposition was LGI1 antibody-positive, the second case was negative for both LGI1 and CASPR2, and in the third case (with extensive C9neo deposition on neural somata and neuronal death), serum for LGI1/CASPR2 retesting unfortunately was not available. Although LGI1 is the predominant target in VGKC-complex antibody-positive limbic encephalitis, some patients have CASPR2 antibodies (Irani et al., 2010a).

There are several limitations of our study: (i) disease duration at specimen collection was always > 1 month and reached a mean value of 21 months. This indicates that our results describe the

![Figure 6](image-url) Immunoglobulin and complement in patients with antibodies to intracellular and surface antigens. Staining for immunoglobulin G (A, C, E, G, I and K) and complement C9 (C9, B, D, F, H, J, L and M) in comparable areas in the intracellular antigen group and surface antigen group. (A and B) Immunoglobulin staining (A) and C9neo deposition (arrowheads in B) in the spinal cord of a positive control patient with neuromyelitis optica (NMO). (C and D) IgG and C9 neo in a patient with paraneoplastic encephalomyelitis with Hu antibodies (Patient Hu/4), a patient with Ma-2 antibodies (E and F, Patient Ma2/1), in non-paraneoplastic encephalitis with GAD65 antibodies (G and H, Patient GAD/3), NMDAR antibodies (I and J, Patient NMDAR/1) or VGKC antibodies (K–M, Patient VGKC/2). IgG stainings show uptake of IgG in neurons in anti-Hu (C), anti-Ma-2 (E), anti-GAD (G) and anti-NMDAR cases (I). In addition, in most cases astrocytes also reveal cytoplasmic staining for IgG (blue arrowheads in C, E and K). In contrast, in the VGKC case (K), staining for IgG is seen on the surface of neurons. Complement C9 staining was negative in all cases except for three out of four anti-VGKC cases where a punctuate staining (L) of neurons in the CA4 area of the hippocampus can be seen. A second VGKC case revealed a punctate staining as well as surface staining (arrowheads) of single cortical neurons (M). Scale bar: (A–L) = 20 μm, (M) = 10 μm.
immunoreaction in the chronic rather than the acute disease stage; (ii) in the patients with limited sampling (epilepsy surgery, brain biopsies), sampling errors may have occurred and (iii) a proportion of the patients had received prior immunosuppressive treatment (details in Table 1), potentially reducing or changing the immunopathological appearance. Yet, the overall consistency of the results suggests that these potential confounders did not exert a major effect.

Despite the limitations that are intrinsic to the study of human material, our work suggests clear immunopathological differences, related to the hypothesized intracellular antigen and surface antigen groups, but even more so between subgroups defined by the nature of the antibodies. Elevated CD8/CD3 ratios in diseases associated with antibodies to intracellular antigens, suggests a cytotoxic T cell-driven pathomechanism. In diseases with antibodies to surface antigens, our findings support a B cell/plasma cell-related pathomechanism, with evidence of a complement-mediated pathogenesis in patients with VGKC-complex antibodies. This immunopathogenic dichotomy parallels other neurological autoimmune disorders such as polymyositis and dermatomyositis, which have a predominant T cell and humorally mediated pathogenesis, respectively (Arahata and Engel, 1984). These observations may contribute to a rational choice in immunological treatments for these disorders.

Acknowledgements

We would like to thank Marianne Leisser, Angela Kury, Ulrike Köck und Claudia Ullmann for expert technical help. We also like to thank Prof. Dr Jeanne Bell (Pathology Directorate, Royal Infirmary Edinburgh, UK) for providing us with patient material and Prof. Dr Horst Urbach, University of Bonn, Department of Radiology/Neuroradiology for providing and discussing magnetic resonance images.

Supplementary material

Supplementary material is available at Brain online.

References


